¶ ALS vs Frontotemporal Dementia: Comparative Investment Analysis
¶ Overview
This page provides a comparative investment analysis of Amyotrophic Lateral Sclerosis (ALS) and Frontotemporal Dementia (FTD), two related neurodegenerative diseases that share common pathological features and overlapping therapeutic approaches. The analysis examines clinical trial activity, pharmaceutical company investment, and therapeutic pipeline developments for both conditions.
This comparative analysis examines the investment landscapes of Amyotrophic Lateral Sclerosis (ALS) and Frontotemporal Dementia (FTD), two neurodegenerative disorders linked by clinical, genetic, and pathological overlap. The analysis compares trial activity, sponsor engagement, therapeutic mechanism coverage, and funding gaps to identify cross-disease investment opportunities and inform strategic prioritization. [1]
¶ Executive Summary
This page provides a side-by-side comparison of the R&D investment landscape for Amyotrophic Lateral Sclerosis (ALS) and Frontotemporal Dementia (FTD), two devastating neurodegenerative conditions that share clinical, genetic, and pathological overlaps. Data is sourced from the local Clinical Trials Index pipeline snapshot refreshed on 2026-03-12T04:24:37. [2]
--- [3]
¶ Portfolio Metrics Comparison
| Metric | ALS | FTD | Differential | [4]
|---|---
------
| Total tracked trials | 1,568 | 380 | ALS has 4.1x more trials |
| Active trials (recruiting/active/not-yet-recruiting) | 454 (29.0%) | 137 (36.1%) | FTD has higher active proportion |
| Completed trials | 746 (47.6%) | 172 (45.3%) | Similar completion rates |
| Late-stage representation (Phase 3/4) | 140 (8.9%) | 23 (6.1%) | ALS has 46% more late-stage trials |
| Biomarker-forward programs | 124 (7.9%) | 67 (17.6%) | FTD has 2.2x more biomarker trials |
| Combination-therapy signals | 0 (0.0%) | 0 (0.0%) | Both lacking |
¶ Key Insights
-
Trial Volume Disparity: ALS has 4.1x more registered clinical trials than FTD (1,568 vs 380), reflecting its higher prevalence and longer research history.
-
Active Portfolio Health: FTD has a higher proportion of active trials (36.1% vs 29.0%), suggesting recent momentum in FTD research despite smaller overall volume.
-
Late-Stage Challenge: Both diseases face significant late-stage translation bottlenecks, with ALS at 8.9% and FTD at just 6.1% of trials in Phase 3/4.
-
Biomarker Investment: FTD shows stronger biomarker adoption (17.6% vs 7.9%), likely driven by genetic stratification advances (GRN, MAPT, C9orf72).
¶ Trial Status Distribution
¶ Side-by-Side Comparison
| Category | ALS Trials | ALS Share | FTD Trials | FTD Share |
|---|---|---|---|---|
| Active/Recruiting | 454 | 29.0% | 137 | 36.1% |
| Not Yet Recruiting | 83 | 5.3% | 16 | 4.2% |
| Recruiting | 273 | 17.4% | 84 | 22.1% |
| Active Not Recruiting | 78 | 5.0% | 24 | 6.3% |
| Enrolling By Invitation | 20 | 1.3% | 13 | 3.4% |
| Historical | 903 | 57.6% | 202 | 53.2% |
| Completed | 746 | 47.6% | 172 | 45.3% |
| Terminated | 103 | 6.6% | 19 | 5.0% |
| Withdrawn | 39 | 2.5% | 10 | 2.6% |
| Suspended | 9 | 0.6% | 0 | 0.0% |
| No Longer Available | 6 | 0.4% | 1 | 0.3% |
| Unknown | 203 | 12.9% | 41 | 10.8% |
¶ Analysis
- Higher FTD Attrition Rate: The ratio of terminated/withdrawn to completed trials is higher in ALS (142/746 = 19.0%) vs FTD (29/172 = 16.9%), suggesting more ALS programs fail during execution.
- Unknown Status: Both diseases have significant unknown-status trials (12.9% for ALS, 10.8% for FTD), indicating registry maintenance challenges.
¶ Therapeutic Mechanism Coverage
¶ Mechanism Distribution Comparison
| Mechanism Cluster | ALS Trials | ALS Share | FTD Trials | FTD Share |
|---|---|---|---|---|
| Mitochondrial biology | 696 | 44.4% | 47 | 12.4% |
| Genetic / gene-targeted | 117 | 7.5% | 71 | 18.7% |
| Amyloid biology | 74 | 4.7% | 14 | 3.7% |
| Tau biology | 37 | 2.4% | 29 | 7.6% |
| Tau aggregation | 37 | 2.4% | 29 | 7.6% |
| Neuroinflammation | 14 | 0.9% | 0 | 0.0% |
| Metal ion dysregulation | 14 | 0.9% | 0 | 0.0% |
| Neurotransmitter systems | 0 | 0.0% | 7 | 1.8% |
| Metabolic pathways | 12 | 0.8% | 4 | 1.1% |
| Synaptic dysfunction | 0 | 0.0% | 4 | 1.1% |
¶ Mechanism Comparison Visualization
¶ Key Mechanism Insights
- ALS is Mitochondria-Dominated: 44.4% of ALS trials target mitochondrial biology, compared to only 12.4% for FTD.
- FTD is Genetics-Forward: 18.7% of FTD trials are gene-targeted vs 7.5% for ALS, reflecting the strong genetic architecture of FTD (C9orf72, GRN, MAPT, TARDBP).
- Tau Focus: FTD has higher relative tau biology investment (7.6% vs 2.4%), consistent with tau-centric pathology in FTD subtypes.
- ALS-Native Mechanisms: Neuroinflammation and metal ion dysregulation are nearly absent from FTD trials but present (though small) in ALS.
¶ Sponsor Landscape Comparison
¶ Sponsor Type Distribution
| Sponsor Type | ALS Trials | ALS Share | FTD Trials | FTD Share |
|---|---|---|---|---|
| Academic/Medical | 843 | 53.8% | 223 | 58.7% |
| Other | 354 | 22.6% | 89 | 23.4% |
| Industry | 292 | 18.6% | 56 | 14.7% |
| Public (NIH/Gov) | 46 | 2.9% | 10 | 2.6% |
| Foundation/Nonprofit | 33 | 2.1% | 2 | 0.5% |
¶ Analysis
- Academic Dominance: Both diseases are heavily academic-led (53.8% ALS, 58.7% FTD), indicating limited pharmaceutical industry penetration.
- Industry Gap: Industry sponsors only 18.6% of ALS trials and 14.7% of FTD trials—significantly lower than diseases with robust pharma pipelines.
- Foundation Engagement: ALS has 4x more foundation-sponsored trials than FTD (2.1% vs 0.5%), reflecting the strong patient advocacy ecosystem (e.g., ALS Association, ALS Finding a Cure).
¶ Top Sponsors Comparison
| ALS Top Sponsors | Trials | FTD Top Sponsors | Trials |
|---|---|---|---|
| Massachusetts General Hospital | 24 | UCSF | 17 |
| Assistance Publique - Hôpitals de Paris | 23 | University of Pennsylvania | 11 |
| Peking University Third Hospital | 22 | Mayo Clinic | 11 |
| Washington University School of Medicine | 16 | Massachusetts General Hospital | 7 |
| Johns Hopkins University | 15 | Nantes University Hospital | 7 |
¶ Key Observations
- US Academic dominance: Both diseases feature major US academic medical centers (MGH, UCSF, UPenn, Mayo) as top sponsors.
- FTD Concentration: FTD research is more concentrated—UCSF alone accounts for 4.5% of all FTD trials.
- International presence: French hospitals (AP-HP, Nantes) appear in both top lists, indicating European engagement.
¶ Funding Gaps and Investment Opportunities
¶ Identified Gaps (Both Diseases)
- Late-stage translation bottleneck: Both diseases have <10% of trials in Phase 3/4, indicating significant attrition between proof-of-concept and registration.
- Combination therapy void: Neither disease has registered combination-therapy trials (0.0%), despite multi-pathway biology suggesting potential synergies.
- Industry underinvestment: <20% industry sponsorship in both diseases represents a major funding gap.
¶ ALS-Specific Gaps
- Underrepresented mechanisms: Tau biology, neuroinflammation, and metal ion dysregulation represent
% combined—potential areas for differentiation. - Biomarker scarcity: Only 7.9% biomarker-forward designs vs 17.6% in FTD.
¶ FTD-Specific Gaps
- Neuroinflammation空白: No registered neuroinflammation trials in FTD, despite growing evidence of microglial involvement.
- Synaptic dysfunction: Only 1.1% of trials target synaptic mechanisms.
- Foundation gap: Near-zero foundation-sponsored trials (0.5%) suggests untapped philanthropy potential.
¶ Cross-Linking to Existing Pages
This analysis should be interpreted alongside:
- ALS Investment Landscape — Full ALS trial breakdown
- FTD Investment Landscape — Full FTD trial breakdown
- ALS Disease Page — Clinical overview of ALS
- FTD Disease Page — Clinical overview of FTD
- ALS-FTD Spectrum — Overlapping syndrome
- Clinical Trials Index — Source data registry
¶ Data Source
This analysis uses the Clinical Trials Index pipeline snapshot from 2026-03-12T04:24:37. For methodology details, see the Clinical Trials Index page.
¶ See Also
- ALS Investment Landscape — Detailed ALS trial analysis
- FTD Investment Landscape — Detailed FTD trial analysis
- ALS-FTD Spectrum — Clinical and pathological overlap
- Comparative Investment Analysis: AD vs PD — Parallel comparison framework
¶ External Links
- ClinicalTrials.gov — Trial registry
- ALS Association — Patient advocacy and research
- The Association for Frontotemporal Degeneration — FTD resources